The Net Margin of Beyondspring Inc (BYSI) is
-2463.29%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-2463.29%
|
| 2024-12-31 |
-1200.80%
|
| 2023-12-31 |
-2463.29%
|
| 2022-12-31 |
-4750.48%
|
| 2021-12-31 |
-33873.89%
|
| Ticker |
Name |
Value |
|
GMDA
|
Gamida Cell Ltd
|
-3531.17%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
SMMT
|
Summit Therapeutics Inc.
|
-11174.75%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
APS.TO
|
Aptose Biosciences Inc
|
4175.00%
|
|
FHTX
|
Foghorn Therapeutics Inc.
|
-240.33%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
ACET
|
ADICET Bio, Inc.
|
-279.27%
|
|
ONCT
|
Oncternal Therapeutics Inc
|
-5029.17%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
AGLE
|
Aeglea Bio Therapeutics Inc
|
-3597.42%
|
|
CRNX
|
Crinetics Pharmaceuticals, Inc.
|
-6046.22%
|
|
APLT
|
Applied Therapeutics Inc
|
-23296.70%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
SPRB
|
Spruce Biosciences, Inc.
|
-1079.94%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
AUTL
|
Autolus Therapeutics PLC
|
-381.40%
|
|
CUE
|
Cue Biopharma, Inc.
|
-96.85%
|
|
GERN
|
Geron Corporation
|
-45.41%
|
|
LCTX
|
Lineage Cell Therapeutics Inc
|
-436.47%
|
|
NLTX
|
Neoleukin Therapeutics Inc
|
-126.36%
|
|
SPRO
|
Spero Therapeutics, Inc.
|
12.83%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
BLU.TO
|
BELLUS Health Inc
|
-475500.00%
|
|
CBMG
|
Cellular Biomedicine Group Inc
|
-14704.70%
|
|
CRDF
|
Cardiff Oncology, Inc.
|
-7732.04%
|
|
FBRX
|
Forte Biosciences, Inc.
|
-158800.00%
|
|
OCX
|
OncoCyte Corp
|
-3225.04%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|